Pituitary Adenomas and Hyperplasia
Definition and Classification
- Pituitary hyperplasia is associated with specific syndromes like McCune-Albright syndrome, Carney complex, X-linked acrogigantism, and can be caused by GH-releasing hormone-secreting tumors, often with MEN1 syndrome, in children and adults 1
- Pituitary hyperplasia can be physiological, such as during pregnancy or puberty, and is characterized by non-neoplastic proliferation of normal pituitary cells 1
- Pituitary adenomas can be classified as microadenomas (<10 mm), macroadenomas (≥10 mm), and giant adenomas (>4 cm) 2
- The following table summarizes the classification of pituitary adenomas:
| Tumor Type | Size | Function |
|---|---|---|
| Microadenoma | <10 mm | Functioning or Non-functioning |
| Macroadenoma | ≥10 mm | Functioning or Non-functioning |
Clinical Presentation
- Children with GH excess from hyperplasia often exhibit tall stature onset before 5 years, disproportionately enlarged hands and feet, teeth separation, acanthosis nigricans, increased BMI, and appetite 1
- Patients with McCune-Albright syndrome and hyperplasia may experience early-onset GH excess, café-au-lait pigmentation, fibrous dysplasia, and precocious puberty 1
Diagnosis
- Pituitary hyperplasia is characterized by diffuse enlargement of the pituitary gland, homogeneous enhancement, and preservation of normal pituitary architecture on imaging 1
- Comprehensive hormonal evaluation, including serum prolactin, IGF-1, GH suppression test, 24-hour urinary free cortisol, nocturnal salivary cortisol, TSH, free T4, FSH, LH, estradiol/testosterone, is essential for both pituitary adenomas and hyperplasia, although the specific tests may vary depending on the suspected condition 1
- Pituitary magnetic resonance imaging (MRI) is fundamental for evaluating microadenomas or other structural anomalies, with indications of clinical suspicion of pituitary adenoma or pituitary hormonal alterations 3
- Bilateral inferior petrosal sinus sampling (BIPSS) is used to confirm the pituitary origin of ACTH in cases of Cushing's syndrome, according to endocrine society guidelines 1
- Ophthalmological evaluation, including visual acuity testing, visual field testing, fundoscopy, and optical coherence tomography, is essential for baseline assessment, especially in patients with severe deficits or tumors compressing the optic chiasm 2, 1
Treatment
- Treatment of pituitary hyperplasia targets the underlying cause, such as removing the stimulus or managing the underlying syndrome, and may involve medical therapy to control hormone excess 1
- Surgical intervention is rarely required for pituitary hyperplasia unless it causes significant mass effect 1
- The Endocrine Society recommends transsphenoidal surgery as the first-line treatment for most adenomas, except prolactinomas, which are primarily treated with dopamine agonists like cabergoline 2
- Medical therapy with dopamine agonists, such as cabergoline, is the first line of treatment for prolactinomas, according to the Endocrine Society 2, 1
- For functioning adenomas, medical therapy based on adenoma type is recommended, including somatostatin analogs, pegvisomant, or cabergoline for GH-secreting adenomas, and ketoconazole, mifepristone, or pasireotide for ACTH-secreting adenomas 1
- Radiation therapy may be indicated in cases of incomplete resection or tumor recurrence, with modalities such as conventional fractionated radiation therapy, stereotactic radiosurgery, or proton beam radiation therapy, with a dose of 45 Gy in 25 fractions, according to radiation therapy society guidelines 1
Monitoring and Follow-up
- Regular monitoring of hormonal levels and serial imaging is essential for both pituitary adenomas and hyperplasia, with periodic ophthalmological evaluation for larger lesions 1
- Lifelong monitoring for tumor recurrence in adenomas and evaluation of health-related quality of life to adapt treatment and psychological support are crucial for optimal patient care 1
- Genetic testing should be offered to all children and young people with pituitary adenomas, particularly important in GH and prolactin-secreting tumors due to high prevalence of genetic abnormalities, as suggested by the Endocrine Society 2
- Strict fluid and electrolyte monitoring, watching for diabetes insipidus, SIADH, or triphasic response, and monitoring for hypopituitarism are crucial after treatment 2
- Evaluation of health-related quality of life is important for adapting treatment and psychological support to the patient's needs 2
Special Considerations
- Patients with pituitary tumors require specialized multidisciplinary care involving endocrinologists, neurosurgeons, and other specialists to prevent serious complications, as recommended by the Endocrinology society 2
- MEN1, AIP mutations, and DICER1 are associated with higher risks of specific pituitary adenoma types, and mental health monitoring is essential, especially for Cushing's disease patients 2
- Overlooking visual assessment, including formal visual field testing, is a common pitfall in the management of pituitary adenomas 2
- Hormonal imbalances, such as cortisol excess in Cushing disease, can lead to brain atrophy, cognitive impairment, and psychological disease, including depression, as stated by the Endocrine Society guidelines 1
- Altered hormone levels, including higher cortisol and TSH, are associated with suicidal behavior, with a moderate strength of evidence, according to a meta-analysis 4
- Patients with mood disorders, which can result from hormonal imbalances, have a significantly higher likelihood of dying by suicide, with 8.62 times higher likelihood in major depression and 8.66 times higher likelihood in bipolar disorder, according to the American Psychiatric Association guidelines 4